ArticleHealth science reports2026
Mapping the HPV Detection Landscape in Botswana: A Narrative Review of Diagnostic Platforms and Their Impact on Cervical Cancer Control.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Cervical cancer is a major public health issue in Botswana, driven by high HIV prevalence and limited screening access. Molecular detection of high-risk human papillomavirus (hrHPV) is crucial for prevention and early diagnosis. The aim of this narrative review is to synthesize studies evaluating seven HPV detection platforms used in Botswana, focusing on diagnostic performance, feasibility, and scalability. Methods: A comprehensive literature search was conducted across PubMed, PMC, Google Scholar, and regional repositories up to July 2025 to identify studies evaluating HPV detection platforms in Botswana. Eligible studies included those assessing molecular HPV assays or genotyping tools in Botswana populations, reporting diagnostic performance or feasibility data. Data extracted covered study population characteristics, sample types, detection platforms, hrHPV prevalence, and performance metrics. Findings were qualitatively synthesized to compare platforms by sample type and application, as heterogeneity precluded meta-analysis. Results: The Cepheid Xpert HPV assay, with near-point-of-care capability, self-sampling suitability, and high sensitivity (96%) and specificity (90%), is well-suited for national programs despite costs of $15-$25 per test. AmpFire, costing $10-$15 per test, requires minimal equipment, offers good field feasibility (92% sensitivity, 88% specificity), and is promising for community deployment. Laboratory-based assays like Roche Linear Array and Abbott RealTime deliver broader genotyping and > 93% sensitivity but require centralized infrastructure. PathoChip microarray detects novel HPV types yet is cost-prohibitive (> $150/test). Double-nested PCR aids retrospective formalin-fixed paraffin-embedded (FFPE) analysis but lacks practicality. These platforms collectively enhance cervical cancer prevention strategies in Botswana. Conclusions: This review identifies feasible HPV detection platforms for Botswana's cervical cancer control. Cepheid Xpert and AmpFire assays offer accurate, affordable, and field-ready options for early diagnosis and wider screening access. Integrating these molecular tools into existing HIV and reproductive health services could enhance prevention, early detection, and progress toward WHO cervical cancer elimination goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.